Vistagen Therapeutics, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 25, 2026, announcing the adoption of a new corporate presentation. The filing indicates that the company began utilizing this updated presentation on the date of the report, with a copy attached as Exhibit 99.1.
The presentation, dated September 2026, outlines the company's strategy to harness the therapeutic power of brain regulation through nose-to-brain neurocircuitry. Vistagen focuses on a class of molecules known as pherines, which are designed to rapidly activate nasal chemosensory neurons. The company states that these molecules modulate neurocircuits from the olfactory bulb to the amygdala and hypothalamus without detectable systemic absorption or brain exposure.
The company highlights four lead clinical-stage product candidates. Fasedienol is the primary candidate for the acute treatment of social anxiety disorder, with a proposed Phase 3 study evaluating its use over six weeks. Itruvone is being developed for major depressive disorder, and Refisolone is for moderate to severe vasomotor symptoms (hot flashes) due to menopause. Additionally, the company lists PH15 for psychomotor/cognitive impairment and PH284 for cancer cachexia.
The filing includes a standard set of forward-looking statements and risk disclosures. These warnings note that clinical trials may not replicate numerical trends, that regulatory approval is not guaranteed, and that the company faces risks related to financing, third-party collaborations, and general economic conditions.
